| pubmed-article:9771745 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9771745 | lifeskim:mentions | umls-concept:C1564874 | lld:lifeskim |
| pubmed-article:9771745 | lifeskim:mentions | umls-concept:C0017296 | lld:lifeskim |
| pubmed-article:9771745 | lifeskim:mentions | umls-concept:C0022951 | lld:lifeskim |
| pubmed-article:9771745 | lifeskim:mentions | umls-concept:C0086022 | lld:lifeskim |
| pubmed-article:9771745 | lifeskim:mentions | umls-concept:C1705099 | lld:lifeskim |
| pubmed-article:9771745 | lifeskim:mentions | umls-concept:C0442335 | lld:lifeskim |
| pubmed-article:9771745 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:9771745 | pubmed:dateCreated | 1998-10-28 | lld:pubmed |
| pubmed-article:9771745 | pubmed:abstractText | Gene therapy is usually reserved for severe and medically refractory disorders because of the toxicity, potential long-term risks and invasiveness of most gene transfer protocols. Here we show that an orally administered adeno-associated viral vector leads to persistent expression of a beta-galactosidase transgene in both gut epithelial and lamina propria cells, and that this approach results in long-term phenotypic recovery in an animal model of lactose intolerance. A gene 'pill' associated with highly efficient and stable gene expression might be a practical and cost-effective strategy for even relatively mild disorders, such as lactase deficiency. | lld:pubmed |
| pubmed-article:9771745 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9771745 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9771745 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9771745 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9771745 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9771745 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9771745 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9771745 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9771745 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9771745 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:9771745 | pubmed:issn | 1078-8956 | lld:pubmed |
| pubmed-article:9771745 | pubmed:author | pubmed-author:YoungDD | lld:pubmed |
| pubmed-article:9771745 | pubmed:author | pubmed-author:SherwinR SRS | lld:pubmed |
| pubmed-article:9771745 | pubmed:author | pubmed-author:LeoniLL | lld:pubmed |
| pubmed-article:9771745 | pubmed:author | pubmed-author:GuoH FHF | lld:pubmed |
| pubmed-article:9771745 | pubmed:author | pubmed-author:DuringM JMJ | lld:pubmed |
| pubmed-article:9771745 | pubmed:author | pubmed-author:KaplittM GMG | lld:pubmed |
| pubmed-article:9771745 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9771745 | pubmed:volume | 4 | lld:pubmed |
| pubmed-article:9771745 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9771745 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9771745 | pubmed:pagination | 1131-5 | lld:pubmed |
| pubmed-article:9771745 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:9771745 | pubmed:meshHeading | pubmed-meshheading:9771745-... | lld:pubmed |
| pubmed-article:9771745 | pubmed:meshHeading | pubmed-meshheading:9771745-... | lld:pubmed |
| pubmed-article:9771745 | pubmed:meshHeading | pubmed-meshheading:9771745-... | lld:pubmed |
| pubmed-article:9771745 | pubmed:meshHeading | pubmed-meshheading:9771745-... | lld:pubmed |
| pubmed-article:9771745 | pubmed:meshHeading | pubmed-meshheading:9771745-... | lld:pubmed |
| pubmed-article:9771745 | pubmed:meshHeading | pubmed-meshheading:9771745-... | lld:pubmed |
| pubmed-article:9771745 | pubmed:meshHeading | pubmed-meshheading:9771745-... | lld:pubmed |
| pubmed-article:9771745 | pubmed:meshHeading | pubmed-meshheading:9771745-... | lld:pubmed |
| pubmed-article:9771745 | pubmed:meshHeading | pubmed-meshheading:9771745-... | lld:pubmed |
| pubmed-article:9771745 | pubmed:meshHeading | pubmed-meshheading:9771745-... | lld:pubmed |
| pubmed-article:9771745 | pubmed:meshHeading | pubmed-meshheading:9771745-... | lld:pubmed |
| pubmed-article:9771745 | pubmed:meshHeading | pubmed-meshheading:9771745-... | lld:pubmed |
| pubmed-article:9771745 | pubmed:meshHeading | pubmed-meshheading:9771745-... | lld:pubmed |
| pubmed-article:9771745 | pubmed:meshHeading | pubmed-meshheading:9771745-... | lld:pubmed |
| pubmed-article:9771745 | pubmed:meshHeading | pubmed-meshheading:9771745-... | lld:pubmed |
| pubmed-article:9771745 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9771745 | pubmed:articleTitle | Peroral gene therapy of lactose intolerance using an adeno-associated virus vector. | lld:pubmed |
| pubmed-article:9771745 | pubmed:affiliation | Department of Molecular Medicine, University of Auckland School of Medicine, New Zealand. Matthew.During@mail.tju.edu | lld:pubmed |
| pubmed-article:9771745 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9771745 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9771745 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9771745 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9771745 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9771745 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9771745 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9771745 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9771745 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9771745 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9771745 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9771745 | lld:pubmed |
